Core Viewpoint - The 2025 China International Service Trade Fair features a health and hygiene services section that showcases innovations in the health industry, highlighting the strong momentum of health industry upgrades in China [1]. Group 1: Health Technology Innovations - The "优促计划" theme exhibition, organized by the Beijing Municipal Health Commission, showcases over 50 medical technology achievements, making it one of the most technologically advanced areas of the health services exhibition [2]. - A handheld smart fundus camera demonstrated at the exhibition can quickly capture eye images and identify over 20 types of eye abnormalities using AI, aiding in early detection of eye diseases [2]. - The intelligent refractive screening device and electronic vision chart for children provide efficient eye health screening solutions, developed through collaboration among various institutions, addressing the needs of different age groups [3][4]. Group 2: Project Acceleration and Commercialization - The "优促计划" aims to accelerate the commercialization of medical technology innovations, with a project reserve of 1,371 and a pool of nearly 10,000 experts, resulting in 69 projects being commercialized with a total contract value of 555 million yuan [4]. - The establishment of a national AI application pilot base in the medical field was announced, featuring 14 common service capabilities and 31 AI application scenarios to enhance the health industry [5]. Group 3: AI and Smart Health Solutions - The AI virtual doctor "融融" provides health consultations and triage suggestions, showcasing the integration of AI in patient care and decision-making processes [5]. - A retinal disease and chronic disease warning system, developed by Beijing Tongren Hospital and Eagle Eye Technology, uses AI to assess overall vascular health through retinal imaging, achieving commercial success in multiple community health centers [6]. Group 4: Advanced Medical Equipment - Siemens introduced the world's first photon-counting CT, which has been installed in over 20 hospitals across 15 provinces, with more than 180,000 patient scans completed [7]. - The exhibition featured various high-end medical devices and AI solutions, including the world's first 5.0T whole-body MRI system and an AI catheter shaping robot, showcasing significant advancements in medical technology [7]. Group 5: Innovative Service Models - Tianjin Pengruili Hospital presented a comprehensive service model that integrates hospital, rehabilitation, and wellness services, demonstrating a multi-faceted approach to healthcare delivery [8]. - The ongoing development of AI and cloud computing technologies is expected to accelerate the transformation of the healthcare industry towards digitalization and personalization, enhancing consumer experiences [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本集團依託於積累十餘年的互聯網醫生平台，應用大數據和人工智能技術鏈接醫 生、患者和藥械企業，提供數字化解決方案，賦能醫療生態，改善醫療質量。 承董事會命 梅斯健康控股有限公司 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 自願性公告 中標 中國某藥企「痛風智管計劃」大型真實世界研究項目 本公告由梅斯健康控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願 發佈，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近期，本公司的子公司上海梅斯醫藥 科技有限公司中標中國某藥企的一項大型真實世界研究項目，該項目旨在「透過前 瞻性與回顧性相結合的觀察性研究，系統評估IL-1β單抗治療痛風急性期與間歇期 患者的有效性與安全性」，項目金額為約人民幣2, ...

Core Viewpoint - The article discusses the challenges faced by companies due to government investment funds that impose "return investment" conditions, which often require businesses to relocate their headquarters or core operations to receive funding, creating a dilemma for many firms [5][6]. Group 1: Government Investment Funds and Their Impact - Government investment funds have become a primary source of capital in the primary market, but they often come with conditions that require companies to relocate to receive investment [5][6]. - The trend of local governments actively seeking to attract companies has intensified, with some officials personally leading efforts to entice businesses to move [7]. - The "return investment" requirement binds venture capital and private equity firms to assist local governments in attracting businesses, which complicates the investment landscape for startups [7][8]. Group 2: Types of Return Investment Requirements - There are three main types of return investment requirements from local guiding funds: establishing branches with minimal operations, setting up factories or sales centers, and relocating headquarters with actual production and tax contributions [8][9]. - The requirement for companies to frequently relocate can disrupt long-term development plans and increase operational costs, making the investment both beneficial and burdensome [9][10]. Group 3: Concerns of Companies Regarding Relocation - Different types of companies have varying considerations regarding relocation, with those having core technological capabilities often possessing stronger bargaining power [11]. - The difficulty of managing operations across different locations is a significant concern for companies, particularly for those in high-tech sectors [10][11]. - Companies that have previously received government subsidies may face demands to return those funds if they relocate, adding another layer of complexity to the decision-making process [12]. Group 4: Effectiveness of Return Investment and Recommendations - The effectiveness of return investment initiatives has been questioned, as many companies that receive funding do not contribute significantly to local economies [14][15]. - There is a call for local governments to shift their focus from short-term metrics like the number of companies attracted to long-term indicators such as tax contributions and employment [16][17]. - Recommendations include adjusting evaluation criteria for local investments to prioritize sustainable economic contributions rather than merely the number of businesses relocated [17].

Market Overview - After a rally driven by the Federal Reserve's interest rate cuts showed signs of fatigue, U.S. stocks fell for two consecutive days, leading the market into a brief stabilization period [1] - Investors are focusing on the upcoming release of Q2 GDP final data, PCE price index, and initial jobless claims this week to gauge the next direction for the stock market [1][5] U.S. Stock Performance - U.S. stock index futures showed little change after two days of pullback, with Intel's stock rising over 5% in pre-market trading due to reports of seeking investment from Apple [1][2] - Chinese concept stocks mostly rose, with XPeng Motors up 3.5% [2][7] - The S&P 500 index managed to break the trend of poor performance typically seen in September, but failed to gain upward momentum, raising concerns about a bottleneck in the current rally [5] Economic Indicators - Piper Sandler's Craig Johnson indicated that while the strong upward trend has not ended, the risk-reward situation is becoming tighter as stock prices rise and potential momentum weakens [6] - The core PCE price index for August is expected to rise by 0.2% month-on-month, lower than July's 0.3%, while the year-on-year increase is anticipated to remain at a high level of 2.9% [6] European Market Performance - European stock markets opened lower, with the pan-European STOXX 600 index down 0.5%, and both the German DAX and UK FTSE 100 indices down 0.4% [8] - The healthcare sector was notably affected, with Siemens Healthineers' stock dropping 6% following a new U.S. investigation into imports of medical supplies [8] Commodity Market Insights - Gold prices remain near record highs, supported by strong demand for traditional safe-haven assets amid geopolitical tensions and potential U.S. government shutdown risks [8] - Silver prices increased by 2%, reaching $44.82 per ounce [14] - Copper prices rose nearly 1%, hitting a new high of $10,457 per ton, the highest since May 2024 [11] Future Projections - Morgan Stanley predicts that gold prices could reach between $4,050 and $4,150 per ounce by mid-2026, driven by lower interest rates and strong central bank demand [9]

Core Viewpoint - The article discusses the transformative impact of immersive technologies like VR and AI on healthcare, highlighting their potential to redefine health boundaries and address various medical conditions, thus opening up opportunities in the trillion-dollar silver economy [1][5]. Group 1: Immersive Therapy - Immersive therapy is being utilized for various treatments, including PTSD, addiction, and social training for children with autism, positioning VR and AR as "second-generation drugs" [8]. - Patients can gradually overcome psychological barriers in a safe environment through virtual scenarios and real-time AI adjustments [8][9]. Group 2: Aging and Health - By 2050, one in six people will be over 65, making brain health a critical investment topic, as longevity does not equate to sustained brain vitality [11]. - Sleep is identified as a key factor in maintaining brain health, with genetics serving as a reminder to focus on cognitive well-being [11]. Group 3: Opportunities in China - China possesses significant latecomer advantages in AI and medical technology, particularly in precision medicine and data application [14]. - The country is poised to rapidly advance in these fields, indicating a strong potential for growth and innovation [14]. Group 4: Digital Therapeutics - The FDA has established a new category for "software as a medical device," allowing doctors to prescribe software, indicating that digital therapies are becoming mainstream [17]. - Immersive medical applications are expected to enter a phase of large-scale implementation within the next 5-10 years [18].

Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. has received approval for its initial public offering (IPO) of A-shares on the ChiNext board, with the issuance price set at RMB 7.05 per share [1][2]. Group 1: Issuance Details - The total number of shares to be issued is 63,193,277 shares, with a strategic placement involving both institutional and retail investors [2][3]. - The strategic placement will consist of 6,300,000 shares allocated to employee asset management plans, accounting for approximately 9.97% of the total issuance [3]. - The initial strategic placement was set at 12,638,655 shares (20.00% of total), but the final amount was adjusted to 9,478,992 shares (15.00%) due to a reallocation to offline issuance [3][4]. Group 2: Subscription and Allocation - The offline initial issuance quantity was 43,603,785 shares, representing 81.18% of the total issuance after deducting the final strategic placement [4]. - The online initial issuance quantity was 10,110,500 shares, accounting for 18.82% of the total issuance [4]. - The final subscription rate for the online issuance was 0.0198%, with a subscription multiple of 5,038.48 times [4]. Group 3: Payment and Lock-up Period - Investors must complete payment for their subscriptions by September 18, 2025, to ensure their allocations remain valid [5][6]. - Online issuance shares will have no restrictions on circulation, while offline shares will have a 10% lock-up period of 6 months [7]. - Strategic placement investors will face a 12-month lock-up period starting from the listing date [7][8].

１、网上投资者申购新股中签后，应根据本公告履行资金交收义务，确保其资金账户在２０２５年９月 １８日（Ｔ＋２日）日终有足额的新股认购资金，不足部分视为放弃认购，由此产生的后果及相关法律 责任由投资者自行承担。投资者款项划付需遵守投资者所在证券公司的相关规定。 网上投资者放弃认购的股份由保荐人（主承销商）包销。 登录新浪财经APP 搜索【信披】查看更多考评等级 特别提示 敬请投资者重点关注本次发行的缴款环节，并于２０２５年９月１８日（Ｔ＋２日）及时履行缴款义 务，具体内容如下： ２０２５年９月１８日 ■ 凡参与本次网上定价发行申购建发致新Ａ股股票的投资者持有的申购配号尾数与上述号码相同的，则为 中签号码。中签号码共有４１，７０７个，每个中签号码只能认购５００股建发致新Ａ股股票。 发行人：上海建发致新医疗科技集团股份有限公司 保荐人（主承销商）：中信证券股份有限公司 ２、本次发行的股票中，网上发行的股票无流通限制及限售期安排，自本次公开发行的股票在深圳证券 交易所上市之日起即可流通。 ４、网上投资者连续１２个月内累计出现３次中签后未足额缴款的情形时，自结算参与人最近一次申报 其放弃认购的次日起６个月（按１８０个自然 ...

一、网上申购情况 保荐人（主承销商）根据深交所提供的数据，对本次网上发行的申购情况进行了统计，本次网上发行有 效申购户数为 13,472,178 户，有效申购股数为 105,070,116,500 股，配号总数为 210,140,233 个，配号起 始号码为000000000001， 截止号码为000210140233。 根据《上海建发致新医疗科技集团股份有限公司首次公开发行股票并在创业 板上市发行公告》公布的 回拨机制，由于网上初步有效申购倍数为10,392.17808 倍，高于100倍，发行人和保荐人（主承销商） 决定启动回拨机制，将扣除最终 战略配售数量后本次公开发行股票数量的20%（向上取整至500股的整 数倍，即 10,743,000 股）由网下回拨至网上。 回拨后，网下最终发行数量为32,860,785股， 约占扣除最终战略配售数量后本次发行数量的 61.18%； 网上最终发行数量为 20,853,500 股，约占扣除最终战略配售数量后本次发行数量的38.82%。回拨后本 次网上发行的中签率为0.0198472227%，申购倍数为5,038.48834倍。 二、回拨机制实施、发行结构及网上发行中签 ...

Core Viewpoint - Recently, Chuangyue Huikang and Haiguang Information signed a strategic cooperation agreement to enhance their capabilities in the medical AI sector [1] Group 1: Strategic Partnership - Chuangyue Huikang's AI products have been adapted and optimized with Haiguang Information's DCU chips, creating a compatible and flexible computational platform [1] - The partnership aims to support the deployment and integration of Chuangyue Huikang's AI applications in the medical field [1] Group 2: Product Development - Chuangyue Huikang has launched dozens of medical AI products to date and plans to continue investing in research and development for public health AI applications, industry intelligent agents, and medical large models [1]

Core Insights - Pathological diagnosis is considered the "gold standard" for disease diagnosis but faces challenges such as complex data, a shortage of professionals, and inconsistent diagnostic standards [1] - SenseTime Medical utilizes a medical large language model "DaYi" as a central intelligence, integrating original pathological models and imaging models to create a "cross-specialty integration" technology system [1] - The company aims to provide systematic solutions to the challenges in the industry through efficient integration and collaborative understanding of pathological images, text reports, and clinical information [1] Company Developments - At the "11th Digital Pathology and Artificial Intelligence Academic Symposium," the CEO presented a report on the innovative paradigm of smart pathology driven by foundational models [1] - SenseTime Medical showcased the performance of its pathological large model, emphasizing the application value of artificial intelligence technology in real medical scenarios [1] - The company is developing a comprehensive "smart pathology" solution based on a multi-modal large model, achieving a closed-loop system through three major technology platforms [3] Future Directions - SenseTime Medical plans to continue exploring the intersection of digital pathology and artificial intelligence, focusing on overcoming key technologies of multi-modal large models [3] - The company aims to facilitate the transition of medical large models from "technically feasible" to "clinically useful" through a pathway of "model foundation - platform empowerment - ecosystem co-construction" [3]